Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Share your knowledge and expertise with your regulatory peers by submitting an in-depth, evidence-based article focusing on key areas and emerging issues in the global regulatory landscape.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Euro Convergence brings regulatory peers from the EU and worldwide together in one forum to gain insights and exchange ideas on the region's most pressing issues. Register today to attend 10-12 May 2021.
Registration is now open for RAPS Convergence 2021! Gather with the regulatory community 12-15 September for four days of learning, engagement, and excitement.
With contributions from more than 30 authors from seven countries, the new edition incorporates a global overview of the field and is designed to help you get the most out of your regulatory intelligence endeavors.
Regipedia is an interactive resource created to benefit RAPS members with 24/7 access to more than 2,300 regulatory terms.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 03 January 2014 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has announced that it will soon convene an advisory committee to discuss whether changes are needed to its "Consumer Updates" in order to make them more impactful and useful to consumers.
At present, consumer updates are used by the agency to address important or pressing topics of public health interest. In recent weeks, FDA has issued Consumer Updates for topics including misbranded dietary supplements, the limitations of breast cancer screening tests, the use of antibiotics in food-producing animals and even important updates to its website.
They are, in other words, one of the main ways FDA interacts directly with the public, as opposed to doing so through the media or health professionals.
But therein lies a challenge for FDA: The complexity of its subject matter, which doesn't always make for quick or easy reads for consumers. It's one thing to communicate with the public if your company sells toys, but quite another if you're an agency charged with making sure people aren't subject to unnecessary harms-or worse.
And according to a recent posting by FDA in the Federal Register, that challenge is one it wants its Risk Communications Advisory Committee (RCAC) to confront at its next meeting in early February 2014.
There, RCAC will be charged with discussing "methods for identifying the impact and increasing the reach of communications on topics of interest to consumers."
In particular, FDA said it was interested in investigating how it can evaluate whether its Consumer Updates are actually reaching the intended audience-consumers-and if the messages are being understood and acted upon appropriately by that same audience.
But the Register notice also indicates that FDA is interested in assessing more than just Consumer Updates. The "Communications on topics of interest to consumers" could potentially include a wide swath of communications, including recall notices, targeted or specific safety warnings, and approval notices.
As with most meetings it convenes, FDA said the complete materials will be available for public consumption at least two days prior to the 3-4 February 2014 meeting date.
Federal Register Notice
Tags: RCAC, Communication, risk
Regulatory Focus newsletters
All the biggest regulatory news and happenings.